Creatine, creatinine, and eGFR: when a supplement changes the test

Creatine is a nutrient and supplement; creatinine is a breakdown product used in common kidney-function equations. Creatine use can raise serum creatinine and make creatinine-based estimated GFR look lower without proving reduced filtration or kidney injury. That possibility is context—not a reason to ignore the result. A clinician can compare trends, urine markers, medicines, illness, muscle and diet factors and, when useful, cystatin C or measured GFR.¹⁴

The laboratory result is an estimate built from a marker

Creatinine enters blood from normal muscle metabolism and is filtered by the kidneys. Common eGFR equations use serum creatinine plus variables such as age and sex to estimate filtration. They do not observe filtration directly. Anything that changes creatinine production, intake, distribution or secretion without the same change in filtration can shift the estimate.

Creatine supplementation adds to the creatine pool, some of which becomes creatinine. Meat intake, muscle mass, intense exercise, hydration, acute illness and certain medicines can also affect context. NIDDK lists muscle and diet among non-GFR determinants and explains that cystatin C has its own non-GFR influences.⁴ No single marker is biologically context-free.

Current studies support an artifact possibility—not automatic reassurance

A 2026 synthesis of 26 studies reported that creatine raised serum creatinine and lowered creatinine-estimated GFR while not changing Cr-EDTA measured GFR, urea, albuminuria or proteinuria in the pooled evidence.¹ Another 2026 analysis found a small average creatinine increase and no significant pooled differences in urea or eGFR, while calling for longer randomized evidence.²

These findings support a plausible estimation effect in studied populations. They do not prove that every creatinine rise in a creatine user is harmless, that creatine cannot affect an individual with kidney disease or interacting exposures, or that decades of use have been studied in every group.

The right move is to improve measurement, not to choose between panic and dismissal.

One low eGFR is not automatically chronic kidney disease

Chronic kidney disease requires evidence of persistent abnormality or kidney damage over time under guideline definitions; a single estimate does not establish chronicity. Conversely, an apparently normal eGFR does not exclude all kidney disease, especially if albuminuria or structural findings are present.

KDIGO recommends creatinine-based estimation as an initial approach and supports combined creatinine-cystatin C estimation when cystatin C is available and greater accuracy is needed; measured GFR has a role in selected circumstances.³ Which step matters depends on the clinical question—routine screening, medicine dosing, surgery, suspected disease or a high-stakes threshold.

Do not manipulate the test without the clinician

Stopping creatine just before a draw can make a number easier to interpret in some contexts, but it can also hide usual exposure or create a nonstandard comparison. Do not start, stop, load or dehydrate to “pass” a kidney test without coordinating the question with the ordering clinician.

Instead, disclose the exact product before the sample. The clinician can decide whether to repeat under standardized conditions, add urine testing, obtain cystatin C, review medicines or pursue another evaluation. If a supplement seller tells customers not to mention use because “doctors misunderstand creatinine,” that undermines safe interpretation.

Product quality and kidney interpretation are different axes

Creatine monohydrate is the most studied form for repeated high-intensity exercise and training outcomes, and NIH ODS summarizes a substantial evidence base and studied safety in healthy adults.⁵ A proprietary “creatine matrix,” pre-workout or wellness blend may add stimulants, electrolytes, botanicals or other actives with separate risks and lab effects.

Record the Supplement Facts panel, lot, manufacturer, third-party certification scope and contaminants testing. A quality seal may support identity and manufacturing checks; it does not guarantee kidney safety for an individual or validate every performance claim.

A wellness clinic should not sell interpretation and the remedy as one shortcut

If a panel flags eGFR and immediately sells hydration IVs, detox products or a supplement switch, ask who independently reviews the result and whether the full record was considered. An isolated equation is not proof of dehydration or toxin accumulation. Repeat and confirmatory testing should answer a defined question, not expand automatically into a large subscription panel.

The result also belongs in procedure planning. If elective surgery, anesthesia, contrast imaging or medication dosing depends on kidney function, the treating clinician should know about creatine and decide whether a more accurate estimate is needed.

1. Separate the words Creatine exposure and serum creatinine are related but not interchangeable; eGFR is calculated from a marker.
2. Preserve the trend Compare dated results, lab methods, supplement exposure and sample conditions instead of one red flag.
3. Look for independent kidney signals Use history, blood pressure, urine findings, medicines and symptoms as clinically appropriate.
4. Improve the estimate when it matters Ask whether combined creatinine-cystatin C or measured GFR would change a high-stakes decision.
5. Coordinate supplement changes Do not manipulate exposure solely to alter the lab; make the test reflect a clinician-defined question.

The citation-ready conclusion is bounded: creatine can confound creatinine-based kidney estimates, but the supplement does not grant permission to dismiss an abnormal result. Better context and a second measurement strategy can resolve the apparent contradiction.